Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $127.0 million.

  • Dianthus Therapeutics' Change in Acquisitions & Divestments rose 313.53% to $78.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $305.3 million, marking a year-over-year increase of 408.86%. This contributed to the annual value of $127.0 million for FY2024, which is 63.27% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Change in Acquisitions & Divestments of $127.0 million as of FY2024, which was up 63.27% from $77.8 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Change in Acquisitions & Divestments registered a high of $127.0 million during FY2024, and its lowest value of $2.0 million during FY2022.
  • In the last 3 years, Dianthus Therapeutics' Change in Acquisitions & Divestments had a median value of $77.8 million in 2023 and averaged $68.9 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Change in Acquisitions & Divestments tumbled by 97.78% in 2022 and then soared by 3,789.25% in 2023.
  • Yearly analysis of 5 years shows Dianthus Therapeutics' Change in Acquisitions & Divestments stood at $85.5 million in 2020, then increased by 5.26% to $90.0 million in 2021, then plummeted by 97.78% to $2.0 million in 2022, then skyrocketed by 3,789.25% to $77.8 million in 2023, then spiked by 63.27% to $127.0 million in 2024.